ABSTRACT
Objective: This research aimed to study the presence of factor V gene G1691A mutation [Factor V Leiden] in SLE pediatric patients with and without complications and to investigate the association between the presence of Factor V Leiden and lupus complications mainly lupus nephiritis in these patients
Subjects and Methods: This study was conducted on 50 Egyptian pediatric patients [48 females and 2 males] who were all diagnosed as SLE according to the American College of Rheumatology criteria. They were enrolled from the Immunological Clinics at Ain shams University Pediatric Hospital and were divided into two groups: Group 1 [control group] of matched age and sex: Including 25 newly diagnosed uncomplicated SLE patients e.g.: arthritis, musculoskeletal and cutaneous lupus. Group 2 [patients group]: Including 25 SLE complicated patient e.g.: nephritis, neurolupus, thrombotic manifestation, cardities and antiphospholipid antibody syndrome. The complications observed in patient group was further classified into lupus nephritis alone or lupus nephritis with other complications [21 patients] or patients with complications other than lupus nephritis [4 patients]
Results: All patients included in this study were subjected after taking their parents' consent to full history taking laying stress on history of complications mainly lupus nephritis. In addition, laboratory investigations which include CBC, tests for confirmation of SLE as ANA, anti dsDNA, C3, lupus anticoagulant, anticardiolipin IgG and IgM and renal function tests as serum creatinine and 24 hrs urinary proteinsm were done. The Factor V gene mutation was determined by the method of PCR-based DNA analysis in both control and patient groups. In control group, there was 1 out of 25 patients having the Factor V Leiden mutation; who had a heterozygous pattern. The prevalence of Factor V Leiden in patients group showed 2 out of 25 patients, both of them had a heterozygous pattern of the gene mutation
Conclusion: This study couldn't demonstrate any correlation between the presence of Factor V Leiden mutation and the presence of complications in SLE patients as there was no statistical significant difference [P >0.05]
ABSTRACT
Background: Lymphoid enhancer-binding factor-1 [LEF1] is a member of the LEF/T-cell factor family of transcription factors and a key mediator of the Wingless-type [Wnt] pathway. It mediates Wnt signals through recruiting beta-catenin and its co-activators to Wnt response elements of target genes. It plays crucial roles in normal hematopoiesis, not only in the development of B and T lymphocytes but also in granulopoiesis
Objectives: The aim of this study was to evaluate of LEF1 expression levels in patients with AML and correlate this expression with clinical data
Methodology: The present study was conducted on 30 de novo adult AML patients and 10 age and sex-matched controls with non-malignant hematological disorders [e.g.: hypersplenism, megaloblastic anemia, immune thrombocytopenic purpura] who attended Hematology/Oncology unit of Ain-Shams University Hospitals during the period from May 2017 till January 2018, after taking the approval of the Scientific and Ethical Committee of Ain Shams University. LEF1 expression levels were measured by quantitative real-time PCR
Results: The present study showed that there was highly statistically significant association between patients and control group in LEF1 expression level. There was positive significant correlation between LEF1 expression level and Hb level and PLT count. While negative significant correlation was found with age, TLC count and peripheral blood blast %. No correlation was found with bone marrow blasts %. There was statistically significant difference between LEF1 expression level and both hepatosplenomegaly. No statistically significant difference was found between LEF1 expression level and Sex or lymphadenopathy
Conclusion: Our study has shown that Lymphoid Enhancer-Binding Factor 1 [LEF-1] is over expressed in AML patients. LEF1 expression might be involved in the process of disease progression, and possibly can serve as a molecular parameter for risk assessment and/or monitoring of treatment in AML patients. Thus, molecular assessment of LEF1 expression at diagnosis may be of value to add to the prognostic work of AML patients
ABSTRACT
Background: obesity and iron deficiency anemia are major health problems that are increasing in Egypt especially in females
Aim of work: this study aimed to evaluate the iron status in obese Egyptian females in comparison to normal weight females
Patients and Methods: forty four obese adult female patients and 44 normal weight healthy females as control group were included in this study. They were all tested for iron profile and CRP using semi quantitative rapid latex agglutination test
Results: the patient group in this study showed a significant lower serum Fe and TSI than the control group, while ferritin was higher in patients than the control group. The comparison between the three groups of obesity showed that the grade III patients had the lowest median value in serum iron and the highest median value in TIBC and ferritin, however no statistical significant differences were detected between the three groups of patients [P>0.05]. Our results showed that 70.4%] of patients had positive CRP with positive correlation between CRP and BMI
Conclusion and Recommendations: obesity is a low inflammatory disease which affects iron profile and increases CRP. Further, study on larger number of cases is recommended to analyze the exact mechanism of iron deficiency anemia in obese female patients